Key result
Guideline-recommended therapies for hospitalized heart failure patients in China show large gaps in effective application, with coronary heart disease and hypertension being the most prevalent causes.
Observational
There remain significant gaps in the real-world application of guideline-recommended therapies for hospitalized heart failure patients in China.
Gaps in guideline-directed HF therapy in China warrant local quality audits; leaves open determinants of underuse and implementation strategies.
Among the hospitalized patients with HF in China, coronary heart disease and hypertension are the mostly prevalent causes. HFpEF accounts for a large proportion of hospitalized patients with HF. HFrEF, HFmrEF and HFpEF have different etiology and clinical features. In real-world, there are still large gaps in the effective application of the guideline recommended therapies to HF patients, especially the non-pharmacological therapy option, which needs to be improved further in China.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) conducted an observational in Heart failure. Guideline-recommended therapies was evaluated. Guideline-recommended therapies for hospitalized heart failure patients in China show large gaps in effective application, with coronary heart disease and hypertension being the most prevalent causes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: